Navitor is pioneering the development of novel therapeutics for a wide range of diseases by targeting the primary cellular pathway involved in nutrient signaling and regulation of cell growth and function

SEC Filings show all

D3

Contact Information


    SEC Form D Funding Events

    DateOfferedSoldType
    2014-08-15$23,521,560$13,521,560Equity
    2014-06-26$23,521,560$13,521,560Equity

    Key Executives

    • Rick Lundberg
      Executive Officer
    • Alan Crane
      Director
    • Jean-Francois Formela
      Director
    • Marian Nakada
      Director
    • Brian Gallagher
      Director
    • George Vlasuk
      Executive Officer, Director